The molecular mechanism: why sotatercept is different from every prior PAH drug

Every PAH drug approved before sotatercept targets vasoconstriction — endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclin pathway agents all reduce vascular tone but do not address the underlying structural remodelling of the pulmonary vasculature. Sotatercept works at an entirely different level: it is an activin receptor type IIA (ActRIIA)–Fc fusion protein that acts as a ligand trap, sequestering activin A, activin B, GDF-8, GDF-11, and other TGF-β superfamily ligands before they can activate the SMAD2/3 signalling cascade.

In healthy pulmonary vasculature, two opposing SMAD pathways maintain homeostasis. The BMPR2–SMAD1/5/8 axis suppresses smooth muscle cell proliferation and promotes apoptosis; the activin–SMAD2/3 axis drives proliferation. In PAH, BMPR2 mutations — present in approximately 70–80% of heritable PAH cases and around 20% of idiopathic PAH cases — reduce SMAD1/5/8 phosphorylation, tipping the balance toward hyperactive SMAD2/3 signalling. The result is uncontrolled pulmonary arterial smooth muscle cell proliferation, endothelial dysfunction, and progressive vascular remodelling that vasodilators cannot reverse.

Preclinical data, as reviewed by researchers including those published in peer-reviewed literature indexed by NIH databases, show reductions in pulmonary vascular resistance and reversal of vascular remodelling in animal models of PAH — including reduction in medial hypertrophy and neointima formation. This anti-remodelling profile, distinct from vasodilation, is the scientific basis for characterising sotatercept as a potential disease-modifying agent rather than purely a symptomatic treatment.

STELLAR Phase III: what the trial actually proved

The STELLAR Phase III trial enrolled 323 patients with WHO functional class II or III PAH who were already on stable background PAH therapy, and randomised them to sotatercept 0.7 mg/kg subcutaneously every 21 days or placebo. The primary endpoint — change in 6-minute walk distance (6MWD) at week 24 — was met with a mean improvement of +40.8 metres versus placebo (p<0.001), a result that directly supported FDA approval in March 2024.

What made STELLAR particularly compelling was the breadth of secondary endpoint success. Pulmonary vascular resistance, NT-proBNP, WHO functional class improvement, and time to death or clinical worsening all significantly favoured sotatercept. This is not a trial where a primary endpoint was met while secondary data were mixed; the hemodynamic, biomarker, and functional benefits moved together in the same direction.

"Sotatercept improved 6-minute walk distance by a mean of +40.8 metres versus placebo — and every key secondary endpoint, including pulmonary vascular resistance, NT-proBNP, WHO functional class, and time to clinical worsening, significantly favoured sotatercept."

Long-term data from the STELLAR extension cohort — patients who completed the 24-week trial and continued into extended follow-up — demonstrate durable improvements in 6MWD, PVR, and NT-proBNP, with some patients achieving near-normal PVR levels of ≤400 dyn·s·cm⁻⁵. The pattern of sustained and progressive hemodynamic improvement over 18–24 months of continuous therapy is consistent with true reversal of pulmonary vascular remodelling rather than simple vasodilation, supporting the disease-modification hypothesis. Regulatory bodies including EMA have been closely tracking these long-term datasets as part of post-approval monitoring requirements.

Beyond approval: SOTERIA, ZENITH, and long-term durability

The SOTERIA open-label extension study, enrolling patients who participated in the earlier PULSAR Phase II and STELLAR Phase III trials, provides the most comprehensive long-term safety and efficacy data available for sotatercept in PAH. Interim data from SOTERIA demonstrate sustained improvements in 6MWD, PVR, and WHO functional class over more than two years of continuous treatment, with no new safety signals beyond those already identified in STELLAR.

The ZENITH result has important implications for treatment algorithms. Prior to this trial, the evidence base for sotatercept was confined to WHO functional class II–III patients on background dual or triple therapy. The demonstration that sotatercept reduces mortality-related events even in the highest-risk patients — those with class IV disease or rapidly deteriorating class III — suggests the mechanism retains efficacy across the full severity spectrum of PAH.

The SOTERIA long-term data also reinforce the treat-to-target concept gaining traction in PAH. Patients who achieved low-risk status at week 24 of STELLAR showed the best long-term outcomes in extended follow-up, suggesting that early and deep hemodynamic response — measured by near-normal PVR (≤400 dyn·s·cm⁻⁵) and NT-proBNP normalisation — may serve as surrogate targets for long-term clinical benefit, analogous to treat-to-target paradigms established in oncology and rheumatology. This framework is increasingly discussed in guidelines from bodies such as WHO and specialist cardiology societies.

Beyond the approved idiopathic and heritable PAH indication, case series data describe sotatercept use in portopulmonary hypertension and drug/toxin-associated PAH subtypes not included in STELLAR. Patients in these series received sotatercept 0.7 mg/kg SC every 21 days on background triple therapy and showed reductions in PVR and NT-proBNP at three to six months, providing mechanistic rationale — dysregulated activin/SMAD2/3 signalling is present across PAH subtypes — for expanded investigation.

HYPERION and the early-PAH frontier

HYPERION is the first Phase III trial designed specifically to evaluate sotatercept as initial combination therapy in treatment-naive PAH patients — comparing it against standard-of-care dual oral therapy in newly diagnosed individuals with WHO functional class II–III disease. Its primary endpoints are PVR reduction and time to clinical worsening, and it represents a direct test of the hypothesis that earlier introduction of an anti-remodelling agent can modify disease progression rather than merely manage symptoms.

The scientific rationale for HYPERION rests on two converging arguments. First, the STELLAR extension and SOTERIA data show that sotatercept's hemodynamic benefits are progressive over time, consistent with ongoing reversal of structural vascular remodelling. Second, WHO functional class II patients represent a population where irreversible remodelling has not yet reached its maximum extent — intervening earlier, before fibrosis and neointima formation become entrenched, may yield more complete and durable hemodynamic normalisation. Risk stratification tools such as COMPERA 2.0 and REVEAL 2.0 are being used to identify these patients in systematic screening programmes, particularly in high-risk populations such as those with systemic sclerosis or BMPR2 mutation carriers.

The right ventricular dimension adds further urgency to earlier intervention. Analysis of echocardiographic data from STELLAR and SOTERIA shows improvements in right ventricular (RV) fractional area change, tricuspid annular plane systolic excursion (TAPSE), and RV size with sotatercept — findings consistent with the activin/TGF-β pathway's known role in RV hypertrophy and fibrosis. Once RV remodelling becomes irreversible, even effective pulmonary vascular therapy may not restore cardiac function. The HYPERION trial's enrolment of treatment-naive patients is therefore not simply a commercial expansion strategy; it reflects a genuine clinical hypothesis that the window for maximal benefit is earlier in the disease course than current approved labelling covers.

Connective tissue disease-associated PAH (CTD-PAH) — particularly systemic sclerosis — is another population of active interest. Patents held by Acceleron/Merck specifically claim the use of sotatercept in CTD-PAH including systemic sclerosis, systemic lupus erythematosus, and mixed connective tissue disease, using the same 0.3–0.7 mg/kg SC every 21-day dosing schedule in combination with existing PAH-targeted therapies. This patent coverage signals a planned label expansion strategy well beyond the current approved indication, as tracked in global patent databases monitored by organisations such as WIPO.

Patent landscape and the intellectual property strategy behind sotatercept

Acceleron Pharma — acquired by Merck — has constructed a layered patent portfolio around sotatercept that covers composition of matter, specific dosing schedules, combination therapy regimens, biomarker monitoring methods, and specific PAH subtypes. The foundational patents claim ActRIIA-Fc fusion protein compositions and their use in treating pulmonary arterial hypertension, with specific dosing schedules of 0.3 mg/kg to 0.7 mg/kg SC every three weeks. Subsequent patents extend protection to the clinical management of adverse events — particularly erythrocytosis — through hemoglobin and platelet count monitoring claims.

Combination therapy patents are strategically important. A key patent application describes combination regimens comprising sotatercept with prostacyclin receptor agonists (e.g., selexipag), prostacyclin analogs (e.g., treprostinil, iloprost), endothelin receptor antagonists (e.g., macitentan, ambrisentan, bosentan), and phosphodiesterase type 5 inhibitors (e.g., sildenafil, tadalafil) — effectively covering sotatercept's use alongside the entire existing PAH drug armamentarium. The patent specifies that background therapy must be stable for at least 90 days prior to initiation, mirroring the STELLAR trial design and creating a tight link between the clinical evidence and the IP claims.

The CTD-PAH patent, filed by Acceleron/Merck, claims methods for treating PAH associated with systemic sclerosis, systemic lupus erythematosus, and mixed connective tissue disease — populations not enrolled in STELLAR but representing a substantial fraction of the total PAH patient population. This filing, combined with the HYPERION trial design targeting treatment-naive patients, outlines a clinical and commercial expansion trajectory that could significantly broaden sotatercept's addressable market beyond the current WHO FC II–III idiopathic/heritable label. IP professionals tracking this portfolio through platforms such as PatSnap's IP analytics suite can monitor prosecution status, citation networks, and freedom-to-operate risks in real time.

The biomarker monitoring patents — covering NT-proBNP, BNP, hemoglobin levels, and platelet counts — are clinically significant beyond their IP value. They codify the treat-to-target approach in patent claims: monitoring NT-proBNP normalisation and managing erythrocytosis are not afterthoughts but core components of the sotatercept treatment protocol. This integration of biomarker strategy into the IP estate reflects a sophisticated understanding of how drug development, clinical practice, and patent protection interact in the biologics space, consistent with frameworks documented by the EMA in its guidance on companion diagnostics and biomarker-stratified trials.